EyePoint Pharmaceuticals (EYPT) Soars 27.6%: Is Further Upside Left in the Stock?

EyePoint Pharmaceuticals (EYPT) shares soared 27.6% in the last trading session to close at $12.12. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 19.1% gain over the past four weeks. Earlier this week, the company announced positive interim 16-week data from the ongoing phase II VERONA study evaluating its lead pipeline candidate, Duravyu, for treating patients with diabetic macular edema. Recently, EyePoint Pharmaceuticals als ...